European Journal of Surgical Oncology
Volume 35, Issue 11 , Pages 1164-1168 , November 2009

Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients

,Accepted 4 February 2009.

References 

  1. Wilkinson N, Scott-Conner CE. Surgical therapy for colorectal adenocarcinoma. Gastroenterol Clin North Am. 2008;37:253–267
  2. Weitz J, Kienle P, Lacroix J, et al. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res. 1998;4:343–348
  3. Beachy SH, Repasky EA. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother. 2008;57:759–775
  4. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem. 2004;37:529–540
  5. Linder S. Cytokeratin markers come of age. Tumor Biol. 2007;28:189–195
  6. Leers MP, Kölgen W, Björklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol. 1999;187:567–572
  7. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer. 2007;56:399–404
  8. Olofsson MH, Ueno T, Pan Y, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res. 2007;13:3198–3206
  9. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008;8:329–340
  10. van Schaik PM, Hermans E, van der Linden JC, Pruijt JR, Ernst MF, Bosscha K. Micro-metastases in stages I and II colon cancer are a predictor of the development of distant metastases and worse disease-free survival. Eur J Surg Oncol sept. 2008.
  11. Cummings J, Ranson M, LaCasse E, et al. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Brit J Cancer. 2006;95:42–48
  12. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 2004;64:1751–1756
  13. Koornstra JJ, Rijcken FE, De Jong S, Hollema H, de Vries EG, Kleibeuker JH. Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas. Histopathology. 2004;44:9–17
  14. Hashimoto S, Koji T, Kohara N, Kanematsu T, Nakane PK. Frequency of apoptosis relates inversely to invasiveness and metastatic activity in human colorectal cancer. Virchows Arch. 1997;431:241–248
  15. Woelfle U, Sauter G, Santjer S, Brakenhoff R, Pantel K. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res. 2004;10:2670–2674
  16. Ebert W, Dienemann H, Fateh-Moghadam A, et al. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem. 1994;32:189–199
  17. Roth GA, Krenn C, Brunner M, et al. Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope M30 in critically ill patients. Shock. 2004;22:218–220
  18. Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer. 2008;123:1991–2006
  19. O'Connor OJ, Cahill RA, Kirwan WO, Redmond HP. The impact of bone marrow micrometastases on metastatic disease-free survival in patients with colorectal carcinoma. Colorectal Dis. 2005;7:406–409

PII: S0748-7983(09)00060-2

doi: 10.1016/j.ejso.2009.02.007

European Journal of Surgical Oncology
Volume 35, Issue 11 , Pages 1164-1168 , November 2009

Article Tools

* Image Usage & Resolution